NVO Novo Nordisk A/S Loading... NONOF

From PFE earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
14:00
Aug 04 ◎
Chris Boshoff Chief Scientific Officer, Pfizer, Inc. PFE Q2 FY26 call
Pfizer's model projects its candidate as potentially superior to Novo's semaglutide in weight loss, a direct competitive claim.
NVO
HIGH
14:00
May 05 ◎
Dr. Albert Bourla Chairman & CEO, Pfizer, Inc. PFE Q1 FY26 call
Pfizer's obesity program (Medcera) is advancing rapidly, with 10 phase three studies planned this year and a target first approval in 2028. — This signals a major push into the obesity market, intensifying competition with Lilly and Novo Nordisk.
NVO
MED
15:00
Feb 03 ◎
Dr. Chris Boshoff Chief Scientific Officer, Pfizer, Inc. PFE Q4 FY25 call
Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile. — Indicates the trial results may be conservative; allowing down-titration in Phase III could improve tolerability and thereby commercial success, competing directly with Lilly and Novo's products.
NVO
MED

About NVO Analyst Coverage

Buzzberg tracks NVO (Novo Nordisk A/S) across 1 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Chris Boshoff, Dr. Albert Bourla, Dr. Chris Boshoff.